Astellas Pharma has been significantly active in the bio-tech market. The company recently announced a $2.2bn gene therapy deal with
AviadoBio Ltd and revealed a strategic collaboration with
Mass General Brigham. Their new drug,
VEOZA (fezolinetant), has garnered attention, presenting noteworthy data at the IMS World Congress on Menopause. The company also received
FDA approval for VYLOY (zolbetuximab-clzb), a treatment for advanced gastric and GEJ cancers. In their pursuit of innovation, Astellas announced the opening of the Cambridge Life Sciences Center and a $90 million West Coast Innovation Center. However, they also plan to close a bio-manufacturing facility, impacting around 100 employees. Amid these developments, an Astellas' employee has been indicted by China's prosecutors, impacting the
company's reputation. Still, the firm continues to push boundaries, aiming to redefine cancer treatment through their work in oncology. Lastly, the healthcare company made news with the unveiling of their digital health product,
DIGITIVA™ for Heart Failure Management, an indication of their increasing focus on combining technology and healthcare.
Astellas Pharma Inc. News Analytics from Thu, 10 Aug 2023 07:00:00 GMT to Wed, 20 Nov 2024 18:00:00 GMT -
Rating 3
- Innovation 5
- Information 6
- Rumor 6
